Barbara Gayle Duncan Insider Trading
Get free email notifications about insider trading for Barbara Gayle Duncan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Barbara Gayle Duncan. Barbara Gayle Duncan is a Director in IMMUNOMEDICS INC ($IMMU) and a Director in Innoviva, Inc. ($THRX) and a CEO in Euthymics Bioscience Inc ($DOVP) and a Director in Euthymics Bioscience Inc ($DOVP) and a President and CFO in Euthymics Bioscience Inc ($DOVP) and a Director in MEDGENICS, INC. ($MDGN) and a Chief Accounting Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and a Chief Financial Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and a Director in Atea Pharmaceuticals, Inc. ($AVIR) and a Director in Adaptimmune Therapeutics PLC ($ADAP) and a Director in Ovid Therapeutics Inc. ($OVID) and a Director in Jounce Therapeutics, Inc. ($JNCE) and a Director in Fusion Pharmaceuticals Inc. ($FUSN).
Address: C/O DOV PHARMACEUTICAL, INC. 150 PIERCE STREET SOMERSET 08873 NJ
Companies in which Barbara Gayle Duncan is an Insider
Adaptimmune Therapeutics PLC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jul 01 2020
$ADAP Market Capitalization: $321.36M
$ADAP Previous Close: $4.53
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Aevi Genomic Medicine, LLC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Latest Transaction: Feb 05 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Atea Pharmaceuticals, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Latest Transaction: Oct 30 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Euthymics Bioscience, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Director, CEO, President and CFO
Holdings: 0 shares
Latest Transaction: May 20 2008
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Fusion Pharmaceuticals Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Latest Transaction: Nov 03 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
IMMUNOMEDICS INC
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Oct 23 2020
$IMMU Market Capitalization: $442.84M
$IMMU Previous Close: $4.23
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Innoviva, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Director
Holdings: 52,318 shares
Latest Transaction: Apr 24 2017
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
INTERCEPT PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Chief Accounting Officer, Chief Financial Officer
Holdings: 30,661 shares
Current Value: $3,482,170
Latest Transaction: Oct 05 2016
$ICPT Market Capitalization: $2.80B
$ICPT Previous Close: $113.57
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Jounce Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Barbara Gayle Duncan: Director
Holdings: 10,000 shares
Current Value: $173,000
Latest Transaction: Sep 16 2020
$JNCE Market Capitalization: $140.99M
$JNCE Previous Close: $17.30
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Ovid Therapeutics Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Director
Holdings: 0 shares
Latest Transaction: Jun 08 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Barbara Gayle Duncan
Sentiment: All, ADAP, GNMX, AVIR, DOVP, FUSN, IMMU, THRX, ICPT, JNCE, OVID
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 03 2020 | FUSN | Fusion Pharmaceuti ... | Duncan Barbara Gayle | Director | Option Exercise | A | 12.40 | 30,000 | 372,000 | 30,000 | |
| Oct 30 2020 | AVIR | Atea Pharmaceutica ... | Duncan Barbara Gayle | Director | Option Exercise | A | 24.00 | 80,000 | 1,920,000 | 80,000 | |
| Oct 30 2020 | AVIR | Atea Pharmaceutica ... | Duncan Barbara Gayle | Director | Option Exercise | A | 24.00 | 80,000 | 1,920,000 | 80,000 | |
| Oct 23 2020 | IMMU | IMMUNOMEDICS INC | Duncan Barbara Gayle | Director | Option Exercise | D | 0.00 | 3,718 | 0 | 0 | |
| Oct 23 2020 | IMMU | IMMUNOMEDICS INC | Duncan Barbara Gayle | Director | Option Exercise | D | 0.00 | 6,540 | 0 | 0 | |
| Oct 23 2020 | IMMU | IMMUNOMEDICS INC | Duncan Barbara Gayle | Director | Sell | D | 0.00 | 49,244 | 0 | 0 | 49.2 K to 0 (-100.00 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 10,000 | 42,100 | 34,271 |